Disclosure of Study Data Sample Clauses

Disclosure of Study Data. Notwithstanding the foregoing, Study data may be disclosed by the Principal Investigator within the Study Team without written consent of Grand River Hospital for purposes of the Study. It is further understood and agreed, that a party may disclose or permit the disclosure of any Study data to its officers, employees, fellows, consultants, and advisors who need to know such Study data for the purposes of the success of the Study, and who are obligated to maintain the confidential nature of such Study data. In the event that the Study Team should come into contact with any information that could reasonably be used to identify any Grand River Hospital patient or staff, the Study Team shall not collect, use or disclose such information, except in accordance with the other provisions of this Agreement and as may be required by applicable law. The Study data period of retention and method of destruction shall be outlined in Appendix D.
AutoNDA by SimpleDocs
Disclosure of Study Data. Collection The Study Team shall identify the specific elements of PHI and PI that will be extracted or collected for the purposes of the Study. The Principal Investigator shall provide a Data Collection Sheet (Appendix C of this Agreement). If data elements change, an amendment to this Agreement must be made at least 7 business days prior to extraction. The Principal Investigator shall provide an amended Data Collection Sheet for each change. Use The Study Team agrees to use the Study data and Source data solely for the purposes and in accordance with the terms and conditions as outlined in the Agreement.
Disclosure of Study Data. SUGEN and Taiho agree to keep each other fully informed on a reasonable basis of the development and commercialization of Products, including but not limited to providing periodic written updates on the progress of each filing for Regulatory Approval. In particular, each such party shall transfer to the other party promptly upon request data, information and results of non-clinical studies performed pursuant to the Collaboration. Additionally, SUGEN shall provide to Taiho a copy of data, information and results generated during those Phase I clinical trials and for which Taiho reimburses a portion of SUGEN's Clinical Trial Costs pursuant to Section 3.6, and Taiho shall provide to SUGEN a copy of information and results generated during any non-clinical and clinical studies conducted by Taiho. [...***...]. If SUGEN, however, [...***...] in an amount equal to [...***...].
Disclosure of Study Data. 6.7. Notwithstanding the foregoing, Study data may be disclosed by the Principal Investigator within the Study Team without written consent of St. Mary’s General Hospital for purposes of the Study. It is further understood and agreed, that a party may disclose or permit the disclosure of any Study data to its officers, employees, fellows, consultants, and advisors who need to know such Study data for the purposes of the success of the Study, and who are obligated to maintain the confidential nature of such Study data.

Related to Disclosure of Study Data

  • Disclosure of Sales The Company will disclose in its quarterly reports on Form 10-Q and in its annual report on Form 10-K the number of Placement Securities sold through the Sales Agent and any Alternative Sales Agent, the Net Proceeds to the Company and the compensation payable by the Company to the Sales Agent and any Alternative Sales Agent with respect to such Placement Securities.

  • Disclosure of Material Information The Company covenants and agrees that neither it nor any other person acting on its behalf has provided or will provide any Purchaser or its agents or counsel with any information that the Company believes constitutes material non-public information, unless prior thereto such Purchaser shall have executed a written agreement regarding the confidentiality and use of such information. The Company understands and confirms that each Purchaser shall be relying on the foregoing representations in effecting transactions in securities of the Company.

  • Disclosure of Agreement 34. The terms of this Settlement Agreement will be treated as confidential by the parties hereto until accepted by the Hearing Panel, and forever if, for any reason whatsoever, this Settlement Agreement is not accepted by the Hearing Panel, except with the written consent of both the Respondent and Staff or as may be required by law.

  • Disclosure of Confidential Information Any Finance Party may disclose:

  • Disclosure of Work Product As used in this Agreement, the term “Work Product” means any invention, whether or not patentable, know-how, designs, mask works, trademarks, formulae, processes, manufacturing techniques, trade secrets, ideas, artwork, software or any copyrightable or patentable works. Executive agrees to disclose promptly in writing to Company, or any person designated by Company, all Work Product that is solely or jointly conceived, made, reduced to practice, or learned by Executive in the course of any work performed for Company (“Company Work Product”). Executive agrees (a) to use Executive’s best efforts to maintain such Company Work Product in trust and strict confidence; (b) not to use Company Work Product in any manner or for any purpose not expressly set forth in this Agreement; and (c) not to disclose any such Company Work Product to any third party without first obtaining Company’s express written consent on a case-by-case basis.

  • Disclosure of Material Matters Immediately upon learning thereof, report to Agent all matters materially affecting the value, enforceability or collectibility of any portion of the Collateral including, without limitation, any Borrower's reclamation or repossession of, or the return to any Borrower of, a material amount of goods or claims or disputes asserted by any Customer or other obligor.

  • No Disclosure of Confidential Information The Consultant acknowledges that the Company’s trade secrets and private processes, as they may exist from time to time, and confidential information concerning the formation and development of the Bank, the Bank’s planned products, technical information regarding the Bank, and data concerning potential customers of and investors in the Bank are valuable, special, and unique assets of the Company, access to and knowledge of which are essential to the performance of the Consultant’s duties under this Agreement. In light of the highly competitive nature of the industry in which the business of the Company is conducted, the Consultant further agrees that all knowledge and information described in the preceding sentence not in the public domain and heretofore or in the future obtained by the Consultant as a result of his engagement by the Company shall be considered confidential information. In recognition of this fact, the Consultant agrees that the Consultant will not, during or after the term of this Agreement, disclose any of such secrets, processes, or information to any person or other entity for any reason or purpose whatsoever, except as necessary in the performance of the Consultant’s duties as a consultant to the Company and then only upon a written confidentiality agreement in such form and content as requested by the Company from time to time, nor shall Consultant make use of any of such secrets, processes or information for Consultant’s own purposes or for the benefit of any person or other entity (except the Company and its subsidiaries, if any) under any circumstances during or after the term of this Agreement.

  • Disclosure of Developments To avoid any disputes over the ownership of Developments, the Employee will provide the Company with a general written description of any of the Developments the Employee believes the Company does not own because they are Excluded Developments. Thereafter, the Employee agrees to make full and prompt disclosure to the Company of all Developments, including, without limitation, Excluded Developments, made during the term of the Employee’s employment with the Company. The Company will hold any information it receives regarding Excluded Developments in confidence.

  • Disclosure of Inventions Each Party will promptly disclose to the other Party all invention disclosures submitted to such Party by its or its Affiliates’ employees describing Joint Inventions and Sole Inventions. Each Party will also respond promptly to reasonable requests from the other Party for more Information relating to such inventions.

  • Non-Disclosure of Third Party Information Executive represents and warrants and covenants that Executive shall not disclose to the Company, or use, or induce the Company to use, any proprietary information or trade secrets of others at any time, including but not limited to any proprietary information or trade secrets of any former employer, if any; and Executive acknowledges and agrees that any violation of this provision shall be grounds for Executive’s immediate termination and could subject Executive to substantial civil liabilities and criminal penalties. Executive further specifically and expressly acknowledges that no officer or other employee or representative of the Company has requested or instructed Executive to disclose or use any such third party proprietary information or trade secrets.

Time is Money Join Law Insider Premium to draft better contracts faster.